CMRAW | Comera Life Sciences Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0193 - 0.0193
52 Week Range	0.0193 - 0.0193
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	1,123,851,250
Market Cap	21,690,329
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-6.08
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	12
Country	USA
Website	CMRAW

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

CMRAW's peers: SLNAW, MLECW

*Chart delayed

Analyzing fundamentals for CMRAW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CMRAW Fundamentals page.

Watching at CMRAW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CMRAW Technicals page.